Lab
Abl Medical Care LLC
Abl Medical Care LLC was paid $1.08M by Medicaid between Jul 2019 and Mar 2023, across 23 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 50% of everything it billed.
33Billing provider infoABL MEDICAL CARE LLC
WINTER SPRINGS, FL 32708
WINTER SPRINGS, FL 32708
33aNPI1295252815assigned 08/24/2017
33bProvider typeClinical Medical Laboratory
28Total paid$1.08M
24GClaims43,836
24DCodes billed23
24AFirst – last monthJul 2019 – Mar 2023
Compared with peers
Next to other Clinical Medical Laboratory providers in Florida
Rank by total paid#39 of 225
Median peer was paid$74K
This provider vs. median15×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 843 | $26K | |
| 2020 | 12,833 | $317K | |
| 2021 | 24,334 | $597K | |
| 2022 | 5,688 | $140K | |
| 2023 | 138 | $470.99 |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 50% | 8,050 | 7,488 | $537K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 35% | 6,922 | 6,007 | $379K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 7.1% | 6,424 | 5,601 | $76K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 3.9% | 7,743 | 7,217 | $42K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 1.5% | 199 | 159 | $16K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.1% | 10,421 | 9,475 | $12K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 410 | 356 | $7K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 641 | 535 | $6K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 62 | 53 | $3K |
| 80053 | Comprehensive metabolic panel | <1% | 276 | 199 | $1K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 16 | 15 | $917.63 |
| 80061 | Lipid panel | <1% | 278 | 200 | $284.61 |
11 more codes
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | <1% | 91 | $228.63 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 148 | $220.16 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 341 | $203.74 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 66 | $202.02 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 144 | $152.43 |
| 82607 | <1% | 63 | $48.80 | |
| 82746 | <1% | 16 | $8.74 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 75 | $4.83 |
| 83540 | <1% | 17 | $3.85 | |
| 99072 | 0% | 1,378 | $0.00 | |
| 99001 | 0% | 55 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTAYLOR, MICHELLE (LABORATORY DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| East Carolina Health-Beaufort INC | Washington, NC | $2.38M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.